IGM Biosciences, Inc.
IGMSDelisted Aug 14, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496323
IGM Biosciences, Inc. was delisted on Aug 14, 2025; its insiders filed their last Form 4 on Aug 18, 2025; 66 institutions reported holding it in 13F filings for Q2 2025, worth $17.9M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by IGM Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for IGM Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baker Julian | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| Baker Felix | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| Baker Bros. Advisors LP | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| Baker Brothers Life Sciences LP | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| 667, L.P. | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| Baker Bros. Advisors (GP) LLC | Other: Former 10% owner and director | 0Indirect | Aug 18, 2025 | 0 |
| Redmile Group, LLC | Director, 10% Owner | 0Indirect | Aug 15, 2025 | 0 |
| Green Jeremy | 10% Owner | 0Indirect | Aug 15, 2025 | 0 |
| Behrens M Kathleen | Director | 0Indirect | Aug 14, 2025 | 0 |
| Hambleton Julie | Director | 0 | Aug 14, 2025 | 0 |
| Lee Michael Stewart | Director | 0 | Aug 14, 2025 | 0 |
| Topsoe Jakob Haldor | Director, 10% Owner | 0Indirect | Aug 14, 2025 | 0 |
| Strohl William | Director | 0 | Aug 14, 2025 | 0 |
| Topsoe Christina Teng | Director, 10% Owner | 0Indirect | Aug 14, 2025 | 0 |
| Topsoe Holding A/S | 10% Owner | 0 | Aug 14, 2025 | 0 |
| Thompson Elizabeth H.Z. | Director | 0 | Aug 14, 2025 | 0 |
| Harler Mary Beth | Chief Executive Officer | 0 | Aug 14, 2025 | 0 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER | 68,169 | Jul 25, 2025 | 0 |
| Tahir Misbah | CHIEF FINANCIAL OFFICER | 170,061 | Jul 25, 2025 | 0 |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER | 26,530 | Jun 20, 2025 | 0 |
| Takimoto Chris H | CHIEF MEDICAL OFFICER | 154,331 | Sep 17, 2024 | 0 |
| Schwarzer Fred | CEO AND PRESIDENT | 250,124 | Sep 17, 2024 | 0 |
| Keyt Bruce | CHIEF SCIENTIFIC OFFICER | 242,948 | Sep 17, 2024 | 0 |
| Gauthier George | Chief Commercial Officer | 39,642 | Dec 1, 2023 | 0 |
| Loberg Michael D | Director | 1,138 | Oct 3, 2023 | 0 |
| Chen Daniel ShinYu | Chief Medical Officer | 116,518 | Jul 6, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 (view filing)4:32 PM ET | Apr 1 | 4 days | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.83M | $23.00 | +$65.0M | –4.67M after | Derivative2 lots |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Topsoe Jakob HaldorDirector, 10% Owner | PPurchase | +1.09M | $23.00 | +$25.0M | –3.36M after | DerivativeDuplicate filing |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Topsoe Christina TengDirector, 10% Owner | PPurchase | +1.09M | $23.00 | +$25.0M | –3.36M after | DerivativeDuplicate filing |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Topsoe Holding A/S10% Owner | PPurchase | +1.09M | $23.00 | +$25.0M | –3.36M after | Derivative |
| Apr 4, 2022 (view filing)9:45 PM ET | Apr 1 | 3 days | Redmile Group, LLC and 1 otherDirector, 10% Owner | PPurchase | +2.61M | $23.00 | +$60.0M | –4.50M after | Derivative |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Loberg Michael DDirector | PPurchase | +21.7K | $23.00 | +$500.0K | New position21.7K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Behrens M KathleenDirector | PPurchase | +60.9K | $23.00 | +$1.40M | New position29.8K after | 3 lots |
| Apr 1, 2022 (view filing) | Mar 30 | 2 days | Keyt BruceChief Scientific Officer | SSale | −7.50K | $28.50 | −$213.8K | −15.8%40.0K after | |
| Nov 3, 2021 (view filing) | Nov 2 | 1 day | Keyt BruceChief Scientific Officer | SSale | −1.33K | $51.37 | −$68.1K | −30.3%3.06K after | |
| Oct 5, 2021 (view filing) | Oct 5 | Same day | Keyt BruceChief Scientific Officer | SSale | −1.24K | $64.10 | −$79.6K | −28.9%3.06K after | |
| Sep 3, 2021 (view filing) | Sep 3 | Same day | Keyt BruceChief Scientific Officer | SSale | −1.24K | $70.69 | −$87.9K | −28.9%3.06K after | |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Hambleton JulieDirector | SSale | −1.00K | $80.00 | −$80.0K | −33.3%2.00K after | |
| Aug 4, 2021 (view filing) | Aug 4 | Same day | Keyt BruceChief Scientific Officer | SSale | −1.24K | $67.00 | −$83.2K | −28.9%3.06K after | |
| Jul 6, 2021 (view filing) | Jul 6 | Same day | Keyt BruceChief Scientific Officer | SSale | −1.25K | $82.50 | −$102.9K | −29.0%3.06K after | |
| Jul 6, 2021 (view filing) | Jul 6 | Same day | Chen Daniel ShinYuChief Medical Officer | SSale | −943 | $82.75 | −$78.0K | −0.8%116.5K after |